HC Wainwright Lowers Earnings Estimates for Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Stock analysts at HC Wainwright lowered their FY2027 EPS estimates for Xeris Biopharma in a research report issued on Monday, November 11th. HC Wainwright analyst O. Livnat now expects that the company will earn $0.19 per share for the year, down from their previous estimate of $0.27. HC Wainwright currently has a “Buy” rating and a $6.60 price objective on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.40) per share.

Separately, Piper Sandler lowered shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a research report on Monday.

Xeris Biopharma Price Performance

XERS stock opened at $3.15 on Tuesday. The firm has a 50-day simple moving average of $2.98 and a two-hundred day simple moving average of $2.52. Xeris Biopharma has a one year low of $1.46 and a one year high of $3.64.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Intech Investment Management LLC purchased a new position in shares of Xeris Biopharma in the 3rd quarter valued at approximately $130,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Xeris Biopharma in the 3rd quarter valued at approximately $237,000. China Universal Asset Management Co. Ltd. increased its holdings in Xeris Biopharma by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock worth $82,000 after buying an additional 11,239 shares during the period. Goldstein Advisors LLC increased its holdings in Xeris Biopharma by 19.7% in the 3rd quarter. Goldstein Advisors LLC now owns 30,425 shares of the company’s stock worth $87,000 after buying an additional 5,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in Xeris Biopharma in the 3rd quarter worth approximately $35,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.